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ABSTRACT
Purpose: Surveys are needed to guide trachoma control efforts in Mozambique, with WHO
guidelines for intervention based on the prevalence of trachomatous inflammation–follicular
(TF) in children aged 1–9 years and the prevalence of trichiasis in adults aged 15 years and
above. We conducted surveys to complete the map of trachoma prevalence in Mozambique.
Methods: Between July 2012 and May 2015, we carried out cross-sectional surveys in 96 evalua-
tion units (EUs) covering 137 districts.
Results: A total of 269,217 individuals were enumerated and 249,318 people were examined using
the WHO simplified trachoma grading system. Overall, 102,641 children aged 1–9 years, and
122,689 individuals aged 15 years and above were examined. The prevalence of TF in children
aged 1–9 years was ≥10% in 12 EUs, composed of 20 districts, covering an estimated total
population of 2,455,852. These districts require mass distribution of azithromycin for at least
3 years before re-survey. The TF prevalence in children was 5.0–9.9% in 17 EUs (28 districts, total
population 3,753,039). 22 EUs (34 districts) had trichiasis prevalences ≥0.2% in adults 15 years and
above, and will require public health action to provide surgical services addressing the backlog of
trichiasis. Younger age, more children resident in the household, and living in a household that
had an unimproved latrine or no latrine facility, were independently associated with an increased
odds of TF in children aged 1–9 years.
Conclusions: Trachoma represents a significant public health problem in many areas of
Mozambique.
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Introduction
Trachoma is an infectious eye disease caused by repeated
conjunctival infection with the bacterium Chlamydia tra-
chomatis. Recurrent infections lead to chronic inflamma-
tion and scarring of the eyelid, altering the eyelid
morphology and, in some people, causing an in-turning
of the eyelashes. When eyelashes rub on the globe of the
eye, trachomatous trichiasis is said to be present. This
process of abrasion can ultimately lead to corneal opaci-
fication with visual impairment or blindness.1,2
Trachoma is the leading infectious cause of blind-
ness worldwide, with the global focus in Sub-Saharan
Africa, particularly its poorest and most isolated rural
communities. In 2013, it was estimated that the African
continent was host to 4 million cases of trichiasis (47%
of all cases globally), with 33 of 56 African countries
thought to be endemic.3 The disease is associated with
low levels of sanitation and inadequate water access.4–6
In general, transmission occurs by close contact within
the home, both directly (via contaminated hands) and
indirectly (on cloths, or on the bodies of eye-seeking
flies).1,7
The World Health Organization (WHO) has tar-
geted trachoma for elimination as a public health pro-
blem by the year 2020, using the SAFE strategy of
Surgery for trachomatous trichiasis; and Antibiotic dis-
tribution, Facial cleanliness and Environmental
improvement in areas where the prevalence of the dis-
ease “trachomatous inflammation—follicular” (TF) in
1–9-year-olds is greater than 5%.
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Mozambique, with a population of over 25 million
people, was thought to have trachoma-endemic districts
in many provinces, but there were few data to guide
elimination efforts. Therefore the Mozambique
Ministry of Health, in collaboration with partners,
undertook population-based surveys to determine the
prevalence of trachoma across all 11 provinces.
Methods
The suspected-trachoma-endemic area of Mozambique
was mapped after dividing it into 96 evaluation units
(EUs). To create these divisions, administrative districts
with relatively low populations were combined with
neighbouring districts, such that each EU had a popu-
lation of approximately 100,000–250,000 people.8 The
surveys were conducted in two phases – a first phase of
five trachoma prevalence surveys in Erati, Memba,
Nacala-a-Velha, Ribaue, and Malema of Nampula
Province, which took place prior to the launch of the
Global Trachoma Mapping Project (GTMP), and a
second phase of 91 surveys conducted with the support
of the GTMP.9
In each EU, a two-stage cluster random sampling
methodology was used. The primary sampling unit was
the village or enumeration area, selected with probabil-
ity proportional to size, where the measure of size was
the total number of households from the 2007 popula-
tion census (data provided by the Mozambique
National Statistics Institute).10 In the second stage,
households were selected, on the day of the survey,
either quasi-randomly using the random walk (first
phase) or randomly using compact segment sampling
(second phase). A list was kept of households from
which some or all inhabitants were absent at the time
of survey, with teams encouraged to return to those
locations later in the day. In keeping with the known
epidemiology of trachoma, urban areas (defined
nationally as communities with more than 5000 inha-
bitants) were excluded from the sampling frame.
At sampled households, all residents aged 1 year and
above were eligible for inclusion. In all 96 EUs, parti-
cipants were examined for clinical signs of trachoma
using the WHO simplified trachoma grading system,
including TF and trichiasis.1,11 In the five first-phase
EUs (Nampula Province), and in nine of the 91 second-
phase EUs (those in Niassa Province, which used ver-
sion 3 of the GTMP training system), data on the
presence or absence of trachomatous scarring (TS)11
were collected either for all subjects (Nampula) or in
eyes with trichiasis (Niassa). (The remaining 82 EUs
were mapped following version 1 of the GTMP training
system, which did not include collection of data on TS.)
Field teams were trained on data collection and (in the
second phase) were required to pass an examination
using the standard GTMP procedures, following a 5-
day training program led by a GTMP-certified master
grader and a GTMP-certified grader trainer; prospec-
tive trachoma graders had to achieve kappa scores of at
least 0.7 in an inter-grader agreement exercise with the
grader trainer, in order to work on a survey.9 Data
recorders were trained to conduct household interviews
and to capture data using Android smartphones
enabled with standard survey forms outlined in the
GTMP protocol. In both phases, survey teams were
taught to establish contact with and obtain permission
from traditional leaders prior to data collection.
Water, Sanitation and Hygiene (WASH) factors
associated elsewhere with trachoma were collected at
household-level by focused interview of household
heads, and by direct observation by trained data recor-
ders. Variables collected were categorized according to
WHO/UNICEF Joint Monitoring Programme stan-
dards, in which an “improved” sanitation facility is
one that hygienically separates excreta from human
contact, and an “improved” water source is one that is
constructed to protect the source from outside
contamination.9,12,13 Due to slight wording differences
in the WASH-related questions used in the two phases
of work, only the 91 second-phase surveys were
included in the risk factor analysis.
Sample size
Using 2007 census data, it was estimated that there
would be 1.59 children aged 1–9 years per household.
Therefore, if teams could visit 32 households per day,
24 clusters would be required per EU to achieve the
sample size of 1019 children needed to estimate a TF
prevalence of 10% with a precision of ±3% at the 95%
confidence level, including a design effect of 2.65 to
account for the clustered design.9
Data collection tools
In the five first-phase EUs, data collection was carried
out using a paper-based questionnaire. In the 91 sec-
ond-phase EUs, data collection was carried out using
Android smartphones, with bespoke GTMP forms
developed in open data kit (ODK) and available
through LINKS (https://gtmp.linkssystem.org/).9
Statistical analysis
For the paper-based census questionnaires, all data
were double-entered into a database using the Census
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and Survey Processing system (CSPro v5 United States
Census Bureau, 2012). Adjustment was carried out
using R (version 3.0.2, The R Foundation for
Statistical Computing, 2013). The overall EU-level
adjusted prevalence was calculated by adjusting the
proportion of children with TF in each cluster, in 1-
year age groups, using the 2007 Mozambique census
data projected to 2010, and calculating the mean of all
such clusters. The same method was used to calculate
the overall adjusted trichiasis prevalence, but with
adjustment for both sex and age in 5-year age groups.
When data on TS were available, we report the preva-
lence of TT: this was possible for 14 EUs. (As noted
above, in 82 of the 96 EUs, data on the presence or
absence of TS in eyes with trichiasis were not collected.)
Confidence intervals around prevalence estimates were
calculated by bootstrapping the adjusted cluster pro-
portions over 10,000 iterations and taking the 2.5th and
97.5th centiles. For the 91 second-phase EUs, analyses
of associations of TF were carried out at individual
level, accounting for clustering at EU, cluster, and
household levels using mixed-effects logistic regression.
Variables were considered for inclusion in the multi-
variable model if significant on univariable analysis at
the p < 0.05 level. A step-wise inclusion approach was
used to build the multivariable model, with variables
retained if significant at the p < 0.05 level (Likelihood
ratio test).
Ethical considerations
Approval for conducting the study was obtained
from the National Committee on Bio-Ethics, the
Provincial Directorates of Health in each province
of Mozambique, and (for the second-phase, GTMP-
supported EUs) the ethics committee of the London
School of Hygiene & Tropical Medicine (references
6319 and 8355). In the paper-based, first-phase sur-
veys, consent forms were signed or finger stamped
by all participants before the start of the data collec-
tion process. For the second-phase, GTMP-sup-
ported surveys, consent was recorded electronically
for all participants. Individuals with active trachoma
and their family members received 1% tetracycline
eye ointment, in accordance with Mozambique
Ministry of Health guidelines. Each person who
took part in the research was thanked and received
a bar of soap plus information about the importance
of daily face washing for the reduction of trachoma
transmission. All patients found to have significant
ocular pathology were referred to the nearest health
centre.
Results
A total of 2378 clusters were visited within the 96 EUs,
with 75,993 households enrolled between July 2012 and
May 2015. In total, 249,318 people aged 1 year or older
were examined from the 269,217 residents living in
those households, representing a coverage of 92.6%. A
total of 138,210 (55.4%) women were examined. A total
of 102,641 children aged 1–9 years and 122,689 indivi-
duals aged 15 years or greater were examined. A greater
proportion (60.8%) of examined subjects aged 15 years
or greater were female. Among the 102,641 children
aged 1–9 years examined, 50,911 (49.6%) were male
and 51,730 (50.4%) were female.
In the 91 second-phase EUs included in the risk
factor analyses, a total of 2240 clusters were surveyed,
covering 70,757 households. A household head was
present and consented to the survey in 70,663 (99.8%
of) households, with 248,494 individuals subsequently
sampled for inclusion, and 228,595 (92.0%) consenting
to examination. 19,325 (7.8%) individuals were resident
in selected households but not present at the time of
survey, and 516 (0.2%) did not consent to examination.
In the five first-phase surveys, a total of 20,723 indivi-
duals provided consent to be examined and were exam-
ined over 138 clusters covering 5233 households.
Table 1 shows, for each EU, the adjusted TF pre-
valence in children aged 1–9 years, and the adjusted
trichiasis prevalence (or TT prevalence, for those EUs
in which TS data could be applied to eyes with trichia-
sis) for adults aged 15 years and above. There were 12
EUs (20 districts, 2,455,852 total population) with TF
prevalences in 1–9-year-olds ≥10%, and 17 EUs (28
districts, 3,753,039 total population) with TF preva-
lences of 5.0–9.9%. In 22 EUs, the trichiasis prevalence
in adults aged 15 years and above was ≥0.2%, the WHO
trichiasis elimination threshold.14
In the 82 surveys in which trachomatous scarring
(TS) did not form part of the examination, a total of
100,904 individuals aged 15 years or greater consented
to examination and were examined. Altogether, 38,522
(38.2%) males aged 15 years or greater were examined,
and 87 were found to have trichiasis (0.22%). Among
the 62,382 (61.8%) females aged 15 years or greater
examined in these surveys, 276 had trichiasis (0.44%).
In the 14 surveys in which TS was included in the
examination, a total of 21,753 individuals aged 15 years
or greater were examined. Of these, 9517 (43.8%) of
those examined aged 15 years or greater were male,
with one case of TT identified (0.01%). A total of
12,236 (56.2%) of those examined aged 15 years or
greater were female, with five cases of TT identi-
fied (0.04%).
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Table 1. Prevalence of trachomatous inflammation—follicular (TF) in children aged 1–9 years and trichiasis in adults aged 15 years
and above, by evaluation unit, Mozambique, 2012–2015. The name given to each evaluation unit is a concatenation of the names of
its constituent districts.
1–9 years ≥15 years
Province Evaluation unit Examined (n) Adjusted TFa (%, 95%CIb) Examined (n) Adjusted trichiasisc prevalence (%, 95%CIb)
Cabo Delgado Ibo-Meluco-Macomia 727 6.6 (3.7–10.5) 1183 0.8 (0.2–1.2)
Cabo Delgado Muidumbe-Mocimboa Praia 769 8.8 (5.3–13.4) 1254 0.7 (0.3–1.2)
Cabo Delgado Pemba Metuge-Mecufi-Quissanga 753 8.4 (5–12.4) 1164 0.4 (0.1–0.7)
Cabo Delgado Nangade-Palma 908 15.7 (10.6–19.8) 1480 1.2 (0.7–1.7)
Cabo Delgado Ancuabe 845 11.6 (7.5–16.8) 1200 0.4 (0.1–0.6)
Cabo Delgado Balama 1019 5.3 (3.7–7.3) 1275 0.8 (0.4–1.1)
Cabo Delgado Chiure 798 13.9 (8.7–19.4) 1181 0.2 (0–0.6)
Cabo Delgado Montepuez 820 7.8 (5–11.5) 1233 0.6 (0.4–1)
Cabo Delgado Mueda 744 12.2 (8.6–16.8) 1313 0.7 (0.3–1.2)
Cabo Delgado Namuno 835 4.8 (2.9–6.6) 1106 0.6 (0.2–1.1)
Gaza Macia 1043 0.3 (0–0.6) 1112 0 (0–0.3)
Gaza Chibuto 866 0.1 (0–0.2) 1088 0.1 (0–0.3)
Gaza Guija-Chigubo-Mabalane 868 0.9 (0–2.4) 1055 0 (0–0.4)
Gaza Chokwe 862 0.2 (0–0.6) 1086 0.2 (0–0.4)
Gaza Manjacaze 935 0 (0–0) 1214 0.3 (0–0.6)
Gaza Massingir-Massangena-Chicualacuala 1042 1.2 (0.3–2.5) 1026 0 (0–0.4)
Gaza Xai-Xai 925 0.1 (0–0.3) 1114 0 (0–0.3)
Inhambane Inhassoro-Govuro-Mabote 1095 1.4 (0.7–2.5) 1342 0.1 (0–0.4)
Inhambane Funhalouro-Panda 879 0.4 (0–1) 1133 0 (0–0.3)
Inhambane Homoine 857 0.1 (0–0.2) 1195 0.2 (0.1–0.4)
Inhambane Inharrime 925 0 (0–0) 1236 0.1 (0.1–0.2)
Inhambane Jangamo 936 0 (0–0) 1213 0.1 (0–0.3)
Inhambane Massinga 819 0.4 (0–1) 1183 0.3 (0–0.5)
Inhambane Morrumbene 894 0.3 (0–0.6) 1222 0.1 (0–0.2)
Inhambane Vilankulo 904 0.9 (0.3–1.4) 1233 0.2 (0–0.4)
Inhambane Zavala 963 0.7 (0.1–1.3) 1318 0.2 (0.1–0.5)
Manica Macossa-Guro-Tambara 1693 10.7 (7.2–14.3) 1280 0.3 (0.1–0.5)
Manica Barue 1344 1.6 (0.5–2.8) 1321 0 (0–0.3)
Manica Macate-Gondola 1394 0.3 (0–0.7) 1240 0.1 (0–0.2)
Manica Machaze 1273 2.6 (1.2–3.9) 1085 0.1 (0–0.3)
Manica Vanduzi-Manica 1432 0.3 (0.1–0.6) 1219 0 (0–0.3)
Manica Mossurize 1218 0.1 (0–0.4) 1110 0 (0–0.3)
Manica Sussundenga 1293 0.4 (0.1–0.8) 1181 0.1 (0–0.3)
Maputo Boane 760 0.6 (0.1–1.3) 1245 0.1 (0–0.3)
Maputo Manhica 1294 1.1 (0.2–2.4) 1452 0 (0–0.3)
Maputo Marracuene 1211 0.6 (0.2–1) 1582 0 (0–0.2)
Maputo Moamba-Magude 768 1 (0.2–2) 1161 0 (0–0.3)
Maputo Matutuine-Namaacha 1125 0.5 (0.1–1.1) 1447 0 (0–0.3)
Nampula Ilha Mozambique-Mossuril 1192 14.5 (9.1–20) 1262 0.1 (0–0.1)
Nampula Mecuburi-Lalaua 1137 3.7 (2.2–5.2) 1212 0.1 (0–0.3)
Nampula Nacaroa-Muecate 1049 6.2 (3.6–9.2) 1211 0.3 (0–0.7)
Nampula Angoche 1193 10.3 (6.1–14.9) 1291 0 (0–0.3)
Nampula Meconta 1000 3.7 (1.7–6.4) 1239 0.1 (0–0.1)
Nampula Mogincual-Liupo 1159 17.1 (11.6–22) 1249 0.1 (0–0.1)
Nampula Mogovolas 1084 3.6 (1.8–5.3) 1273 0.1 (0–0.2)
Nampula Moma-Larde 1209 8.3 (6.3–10.4) 1288 0.8 (0.2–1.9)
Nampula Monapo 1114 7.6 (4.5–10.7) 1265 0 (0–3)
Nampula Murrupula 1035 2.7 (1.3–4.4) 1222 0 (0–0.3)
Nampula Nampula 984 2.9 (1.3–4.8) 1198 0 (0–0.3)
Nampula Ribauee 1964 1.3 (0.7–1.7) 2335 0 (0–0.2)d
Nampula Malemae 1680 1.1 (0.5–1.8) 2227 0 (0–0.2)d
Nampula Membae 1846 11.9 (9–16) 2300 0 (0–0.2)d
Nampula Eratie 1581 8.4 (6.3–11.4) 2285 0 (0–0.2)d
Nampula Nacala-A-Velhae 1858 9.4 (7.3–11.5) 2647 0 (0–0.1)d
Niassa Cuamba 1094 2.1 (0.9–3) 1119 0 (0–0.3)d
Niassa Lichinga 1016 1.2 (0.4–2) 978 0 (0–0.4)d
Niassa Mandimba 1395 1.4 (0.6–2.5) 1142 0 (0–0.3)d
Niassa Mecanelhas 1308 1.9 (1–2.6) 1194 0.1 (0–0.4)d
Niassa Sanga-Lago 1120 0.5 (0.2–0.9) 1106 0 (0–0.3)d
Niassa Magune-Marupa 985 2.4 (1.1–4.1) 1047 0.1 (0–0.2)d
Niassa N’gauma 1139 3.3 (1.7–5.3) 1086 0 (0–0.4)d
Niassa Maúa-Nipepe-Metarica 1245 1.4 (0.7–2.4) 1206 0 (0–0.3)d
Niassa Muembe -Mecula-Mavago 1172 0.7 (0.1–1.5) 1113 0 (0–0.3)d
Sofala Buzi 1063 0 (0–0) 1086 0 (0–0.4)
Sofala Caia 1449 2.1 (1.3–3.3) 1224 0.2 (0–0.5)
Sofala Machanga-Chibabava 979 0.8 (0.2–1.5) 1111 0 (0–0.3)
Sofala Dondo 1128 0.4 (0.1–0.7) 998 0 (0–0.4)
Sofala Gorongoza 1292 1.2 (0.4–2.4) 1173 0 (0–0.3)
Sofala Cheringoma-Muanza-Marromeu 1510 4.1 (2.8–5.7) 1306 0.1 (0–0.3)
Sofala Chemba-Maringue 1391 6.9 (4.8–9.5) 1139 0.2 (0–0.4)
Sofala Nhamatanda 1197 1 (0.3–1.8) 1081 0.4 (0–1.1)
Tete Angonia 834 3 (1.2–5.6) 1272 0.2 (0–0.5)
(Continued )
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EU-level prevalences of TF in children aged
1–9 years and trichiasis (or TT) in adults aged
15 years and above are shown in Figures 1 and 2,
respectively. In 74 EUs, the trichiasis (or TT) preva-
lence was less than the WHO elimination threshold of
<0.2% of the population aged 15 years and above, and
in 67 EUs, the TF prevalence in children aged 1–9 years
was less than the 5% threshold for elimination. Overall,
59 EUs had both a TF prevalence <5% in children aged
1–9 years and a trichiasis prevalence of <0.2% of those
aged 15 years and above. Among the 22 EUs with
trichiasis prevalences in adults ≥0.2%, seven had TF
prevalence >10% and seven had TF prevalence between
5.0 and 9.9%.
Risk factor analysis
TF risk factors
Full univariable results for the outcome of TF in chil-
dren aged 1–9 years are shown in Table 2. Among the
91 surveys conducted in the second phase, TF preva-
lence was 4% among boys and 4% among girls. A
multivariable analysis found that younger age, living
with more children aged 1–9 years in the household,
and living in a household with unimproved or no
latrine facilities (including use of the bush or field)
was independently associated with TF in the same age
group (Table 3).
Discussion
The GTMP may be the largest field-based infectious
disease mapping project ever attempted, and the work
conducted in Mozambique was its largest single con-
stituent project. Altogether, 91 separate standardised
population-based trachoma prevalence surveys, invol-
ving the individual examination of a total of more than
200,000 people of all ages, were carried out by trained
and certified field teams; complementing five trachoma
prevalence surveys previously carried out in 2012. The
successful completion of this work is an excellent indi-
cation of the Mozambique programme’s readiness to
proceed to national elimination of trachoma as a public
health problem.
Slightly more women than men were examined. This
reflects the demographic structure of the Mozambican
population, in which there are more women than men,
but also a higher probability of women being at home
Table 1. (Continued).
1–9 years ≥15 years
Province Evaluation unit Examined (n) Adjusted TFa (%, 95%CIb) Examined (n) Adjusted trichiasisc prevalence (%, 95%CIb)
Tete Chiuta-Cahora Bassa 892 5.7 (3.7–8.3) 1210 0.1 (0–0.1)
Tete Changara 903 9.9 (6.9–12.9) 1163 0.2 (0–0.5)
Tete Chifunde 1042 4.1 (2.5–6) 1228 0.1 (0–0.3)
Tete Macanga 1063 3.6 (2.1–5.2) 1269 0 (0–0.3)
Tete Magoe-Zumbu 845 5.2 (2.9–8.3) 1253 0.2 (0–0.4)
Tete Maravia 879 1.9 (0.8–3.1) 1224 0 (0–0.3)
Tete Moatize 1006 4.7 (2.8–6.8) 1200 0.2 (0–0.5)
Tete Doa-Mutarara 1073 9.7 (7.2–13) 1248 0.1 (0–0.2)
Tete Tsangano 836 1.7 (0.8–2.9) 1193 0 (0–3)
Zambezia Chinde-Luabo-Inhassunge 1613 19.8 (15.6–24.1) 2200 0.2 (0–0.5)
Zambezia Gile 935 2.3 (0.9–3.4) 1217 0 (0–3)
Zambezia Gurue 797 3.3 (1.9–4.7) 1098 0 (0–0.4)
Zambezia Ile-Mulevala 829 1.2 (0.3–2.3) 1150 0.3 (0–0.7)
Zambezia Lugela 794 2 (0.6–3.3) 1231 0.1 (0–0.3)
Zambezia Mocubela-Maganja da Costa 856 10.2 (6.5–13.3) 1188 0.2 (0–0.4)
Zambezia Milange 872 3.7 (1.9–5.9) 1169 0 (0–0.3)
Zambezia Mocuba 896 1.6 (0.8–2.7) 1214 0 (0–0.3)
Zambezia Molocue 821 1.8 (0.9–2.5) 1170 0 (0–0.3)
Zambezia Mopeia 853 6.9 (4.4–10.3) 1196 0 (0–0.3)
Zambezia Morrumbala 865 7 (3.9–11.1) 1168 0.1 (0–0.3)
Zambezia Namacurra 770 3.4 (1.6–5.7) 1263 0.2 (0–0.4)
Zambezia Namaroi 774 2.7 (1–4.4) 1147 0 (0–0.3)
Zambezia Nicoadala 1438 3.9 (2.2–6) 1713 0.1 (0–0.1)
Zambezia Pebane 751 14.1 (9.9–19.7) 1210 0.3 (0–0.9)
aPopulation-based trachomatous inflammation–follicular (TF) prevalence derived from cluster-level proportions adjusted for age in 1 year agebands using the
latest available census data
b95% Confidence intervals estimated by bootstrapping adjusted cluster-level proportions over 10,000 replicates. Zero-count estimate upper confidence
interval limits estimated as a one-sided 97.5% exact binomial confidence interval.
cPopulation-based trichiasis prevalence derived from cluster-level proportions adjusted for sex and age in 5 year agebands using the latest available census
data
dData on trachomatous scarring (TS) recorded for all subjects, or for eyes with trichiasis (see text), in these surveys, so the trichiasis prevalence estimates here
may be accurately referred to as trachomatous trichiasis (TT) prevalence estimates.
eFirst-phase, paper-based surveys.
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at the time of data collection. (In the areas surveyed,
during the day, the majority of men work in the fields.)
Most of the surveys reported in this paper were
baseline surveys, i.e., conducted prior to the initiation
of any community-based interventions against tra-
choma. The exceptions were the nine surveys done in
Niassa Province, where a previous (July 2011) pro-
vince-level survey had estimated the TF prevalence in
1–9-year-olds to be 32% [unpublished Ministry of
Health data]. On the basis of that estimate, mass treat-
ment with azithromycin was undertaken in 10 of
Niassa’s 16 districts in 2013 (with 9/10 districts
achieving >80% coverage), and in all 16 districts in
2014 (with 6/16 districts achieving >80% coverage).
Whether the 2011 estimates were overestimates or the
effect of those rounds of mass treatment was large – or
both – is difficult to say, but it is notable that each of
the Niassa EUs for which we conducted impact surveys
in 2015 (this study) returned estimated TF prevalences
of <5%. Surveillance surveys should be undertaken in
these EUs in 2017.
In total, of 96 EUs, 12 had TF prevalences ≥10%
among children aged 1–9 years. These 12 EUs, com-
posed of 20 districts, should have mass treatment with
Figure 1. Prevalence of trachomatous inflammation–follicular (TF) in those aged 1–9 years in 96 population-based prevalence
surveys, Mozambique, 2012–2015.
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azithromycin annually for the next 3 years.15 In addi-
tion, 17 EUs, composed of 28 districts, had TF preva-
lences between 5.0 and 9.9% and may be considered for
one round of azithromycin treatment before re-survey,
following informal recommendations from the
International Trachoma Initiative. All 29 of these EUs
also need implementation of the F&E components of
the SAFE strategy. Overall, 67 EUs had a TF prevalence
in children aged 1–9 years below the WHO elimination
threshold, yet eight of these EUs had a trichiasis
prevalence ≥0.2% of those aged 15 years and above,
suggesting that active trachoma is likely to have been a
public health problem there in the past.
A total of 77% of the EUs surveyed (74/96) had a
trichiasis (or TT) prevalence below the threshold
defined by WHO to indicate a public health problem:
0.2% in adults aged 15 years and above.14 The EU
comprising Nangade and Palma districts in Cabo
Delgado Province had a trichiasis prevalence in those
aged 15 years and above of >1%. The reason for the
Figure 2. Prevalence of trichiasis in those aged 15 years and above in 96 population-based prevalence surveys, Mozambique,
2012–2015. In 14 evaluation units (hatched), prevalence categories shown are for trachomatous trichiasis (TT), defined as trichiasis
and (in the same eye) either (a) trachomatous conjunctival scarring (TS); or (b) the examiner’s inability to evert the eyelid to look for
TS (with the difficulty in eversion presumed to be due to TS). In the other 82 evaluation units, prevalence categories shown are for
all-trichiasis, regardless of the presence or absence of TS.
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much higher burden of trichiasis in this area is unclear.
In the 22 EUs with trichiasis prevalences ≥0.2% in
adults, resources should be made available to ensure
that individuals who need surgery have access to a high
quality service provided, if possible, at no cost to the
recipient.
We found that younger children, and children shar-
ing a household with larger numbers of children had
Table 2. Univariable mixed-effects logistic regression analysis of the outcome trachomatous inflammation–follicular (TF)
in children aged 1–9 years against putative risk factors, using data from 91 population-based prevalence surveys, Global
Trachoma Mapping Project, Mozambique, 2012–2015.
Variable Examined (n) TF cases (%) Odds ratio (95% CI)a p-valueb
Age
1–4 42,919 2377 (5.5) 2.16 (2.01–2.33) <0.0001
5–9 50,793 1386 (2.7) 1
Sex
Male 46,532 1859 (4.0) 1
Female 47,180 1904 (4.0) 1.03 (0.96–1.10) 0.43
Number of children aged 1–9 years in household
1–3 76,899 2900 (3.8) 1
≥4 16,813 863 (5.1) 1.44 (1.31–1.57) <0.0001
Latrine typec
Improved 16,040 382 (2.4) 1 <0.0001
Unimproved 36,684 1160 (3.2) 1.21 (1.07–1.37)
No facilities, bush or field 40,988 2221 (5.4) 1.46 (1.30–1.64)
Latrine accessd
Shared latrine 6681 172 (2.6) 1.05 (0.86–1.29) <0.0001
Private latrine 42,920 1182 (2.8) 1
No structure, outside near the house, in the bush or field 44,111 2409 (5.5) 1.25 (1.13–1.38)
Time to source of water for face-washingd
All face-washing done at source 307 6 (1.9) 1.51 (0.60–3.78) 0.2226
<30 mins round-trip 43,251 1486 (3.4) 1
≥30 mins round-trip 50,154 2271 (4.5) 1.09 (0.98–1.22)
Time to source of water for drinkingd
<30 mins round-trip 43,084 1485 (3.4) 1
≥30 mins round-trip 50,628 2278 (4.5) 1.08 (0.97–1.21) 0.1576
Source of water for drinking
Improved water source 53,561 1911 (3.6) 1 0.112
Unimproved water source 17,930 934 (5.2) 1.11 (0.95–1.30)
Surface water (river, lake, dam) 22,221 918 (4.1) 1.16 (0.99–1.36)
Source of water for face-washing
Improved water source 52,367 1872 (3.6) 1 0.0944
Unimproved water source 18,240 949 (5.2) 1.12 (0.96–1.31)
Surface water (river, lake, dam) 22,835 942 (4.1) 1.17 (1.00–1.35)
aUnivariable odds ratio and 95% confidence interval against the outcome trachomatous inflammation—follicular in children aged 1–9 years.
Analysis carried out at individual level.
bWald’s test
cDirect observation by recorders
dSelf-reported estimates from household head.
Table 3. Multivariable mixed-effects logistic regression analysis of the outcome trachomatous
inflammation–follicular (TF) in children aged 1–9 years against putative risk factors, using data
from 91 population-based prevalence surveys, Global Trachoma Mapping Project, Mozambique,
2012–2015.
Variable Odds ratio (95% CI)a p-valueb
Age
1–4 2.19 (2.03–2.36) <0.0001
5–9 1
Number of children aged
1–9 years in household
1–3 1
≥4 1.51 (1.38–1.65) <0.0001
Latrine typec
Improved 1 <0.0001
Unimproved 1.24 (1.03–1.49)
No facilities, bush or field 1.45 (1.22–1.73)
aMultivariable odds ratio and 95% confidence interval against the outcome trachomatous inflammation–follicular
in children aged 1–9 years. Analysis carried out at individual level.
bLikelihood ratio test of inclusion/exclusion in the full multivariable model.
cDirect observation by recorders.
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higher odds of TF in this population. This is in keeping
with the belief that younger children act as the reservoir
of infection for ocular C. trachomatis,16 and that close
contact with more children is likely to facilitate spread.-
17–20 In addition, we found that unimproved latrine
facilities, or living in a household with no latrine facil-
ities, was an independent association of TF in children.
Similar associations have been noted elsewhere, both
prior to21–24 and within the GTMP,20,25–27 and are in
keeping with the belief that latrine facilities of a given
standard limit the reproductive potential of the flies
associated with transmission.5,28,29
At larger scale, it is noted that active trachoma exists
as a public health problem in Mozambique in an arc of
endemicity stretching from Cabo Delgado in the coun-
try’s north-east to Tete in the west. We are unsure as to
the reasons for this phenomenon, and will work with
local epidemiologists and international experts to try to
generate an explanation.
Active trachoma is a public health concern for 48
districts of Mozambique. 6.2 million people live in
those districts. It is essential to undertake distribution
of azithromycin, improve sanitation services, push the
importance of facial cleanliness and improve water
access in these areas in order to eliminate trachoma.
In addition, there is a significant backlog of individuals
with trichiasis who urgently need corrective eyelid sur-
gery in order to preserve their remaining vision.
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